Maling T J, Siebers R W
Department of Medicine, Wellington School of Medicine, New Zealand.
J Cardiovasc Pharmacol. 1990;16 Suppl 7:S50-1.
The reported inverse relationship between fractional urinary clearance of lithium (FCLi) and erythrocyte sodium-lithium countertransport (Na-Li CT) in normotensive and hypertensive subjects suggests that Na-Li CT may be a marker of proximal tubular sodium reabsorption. We have refuted this hypothesis in a multiracial study of 57 Caucasian and 48 Maori normotensive and hypertensive males aged 20-40 years. Na-Li CT was measured in vitro by standard Li efflux methodology, and in vivo by the Li cell:plasma (Li C:P) ratio 24 h after a 1 g oral dose of lithium carbonate. The Na-Li CT and Li C:P ratio were not significantly different in the two races and were strongly correlated within race, confirming the validity of the Li C:P ratio as an in vivo index of in vitro Na-Li CT. There was no correlation in either race between in vitro or in vivo erythrocyte membrane sodium transport indices and FCLi.
在血压正常和高血压受试者中,锂的尿清除分数(FCLi)与红细胞钠-锂逆向转运(Na-Li CT)之间报告的负相关关系表明,Na-Li CT可能是近端肾小管钠重吸收的一个标志物。在一项针对57名20至40岁血压正常和高血压的白种男性以及48名毛利男性的多种族研究中,我们反驳了这一假设。通过标准的锂流出方法在体外测量Na-Li CT,并在口服1克碳酸锂24小时后通过锂细胞:血浆(Li C:P)比值在体内测量。Na-Li CT和Li C:P比值在两个种族中没有显著差异,并在种族内呈强相关,证实了Li C:P比值作为体外Na-Li CT体内指标的有效性。在两个种族中,体外或体内红细胞膜钠转运指标与FCLi之间均无相关性。